Laura M. Jacobsen

5.8k total citations · 2 hit papers
72 papers, 1.9k citations indexed

About

Laura M. Jacobsen is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Laura M. Jacobsen has authored 72 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Endocrinology, Diabetes and Metabolism, 47 papers in Genetics and 42 papers in Surgery. Recurrent topics in Laura M. Jacobsen's work include Diabetes Management and Research (48 papers), Diabetes and associated disorders (46 papers) and Pancreatic function and diabetes (39 papers). Laura M. Jacobsen is often cited by papers focused on Diabetes Management and Research (48 papers), Diabetes and associated disorders (46 papers) and Pancreatic function and diabetes (39 papers). Laura M. Jacobsen collaborates with scholars based in United States, Canada and Sweden. Laura M. Jacobsen's co-authors include Desmond Schatz, Araz Rawshani, Barbara J. Anderson, Dana Dabelea, Soffia Guðbjörnsdóttir, Åke Lernmark, Anastasia Katsarou, Ezio Bonifacio, Michael J. Haller and Mark A. Atkinson and has published in prestigious journals such as Journal of Neuroscience, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Laura M. Jacobsen

64 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Type 1 diabetes mellitus

2017 938 citations Laura M. Jacobsen, Desmond Schatz et al. profile →
Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement Collaborative

2023 76 citations Osagie Ebekozien, Janine Sanchez et al. Diabetes Technology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura M. Jacobsen United States	19	1.1k	974	901	256	182	72	1.9k
Sonia Toni Italy	22	811 0.8×	732 0.8×	786 0.9×	374 1.5×	60 0.3×	62	1.6k
Bruce R. King Australia	30	1.9k 1.8×	1.0k 1.1×	969 1.1×	162 0.6×	58 0.3×	89	2.6k
Tomasz Klupa Poland	27	1.4k 1.3×	1.1k 1.1×	1.1k 1.2×	559 2.2×	42 0.2×	133	2.5k
Halis Kaan Aktürk United States	26	1.2k 1.1×	628 0.6×	674 0.7×	127 0.5×	52 0.3×	108	1.8k
Thomas Donner United States	17	720 0.7×	347 0.4×	461 0.5×	253 1.0×	228 1.3×	29	1.4k
Séamus Sreenan Ireland	28	1.5k 1.4×	722 0.7×	1.1k 1.2×	949 3.7×	128 0.7×	81	3.3k
Susan J. Burke United States	23	311 0.3×	387 0.4×	508 0.6×	594 2.3×	281 1.5×	64	1.8k
Marc Roger France	26	723 0.7×	462 0.5×	342 0.4×	603 2.4×	130 0.7×	53	2.0k
Mark P. Christiansen United States	30	2.0k 1.9×	820 0.8×	1.1k 1.2×	324 1.3×	26 0.1×	53	3.0k
Henry Rodriguez United States	27	3.9k 3.7×	3.0k 3.1×	2.5k 2.7×	589 2.3×	521 2.9×	50	5.2k

Countries citing papers authored by Laura M. Jacobsen

Since Specialization

Citations

This map shows the geographic impact of Laura M. Jacobsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura M. Jacobsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura M. Jacobsen more than expected).

Fields of papers citing papers by Laura M. Jacobsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura M. Jacobsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura M. Jacobsen. The network helps show where Laura M. Jacobsen may publish in the future.

Co-authorship network of co-authors of Laura M. Jacobsen

This figure shows the co-authorship network connecting the top 25 collaborators of Laura M. Jacobsen. A scholar is included among the top collaborators of Laura M. Jacobsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura M. Jacobsen. Laura M. Jacobsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sims, Emily K., David Cuthbertson, Lauric Ferrat, et al.. (2025). IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. Diabetologia. 68(5). 993–1004. 2 indexed citations

Igudesman, Daria, Laura M. Nally, Alyssa Grimshaw, et al.. (2025). Dietary Patterns for Weight and Glycemic Management in Persons With Type 1 Diabetes: A Meta-analysis of Clinical Trials. The Journal of Clinical Endocrinology & Metabolism. 110(11). 3289–3300. 2 indexed citations

Haller, Michael J., Kirstine J. Bell, Rachel Besser, et al.. (2024). ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes. Hormone Research in Paediatrics. 97(6). 529–545. 18 indexed citations

Sims, Emily K., David Cuthbertson, Laura M. Jacobsen, et al.. (2024). Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals. The Journal of Clinical Endocrinology & Metabolism. 109(8). 2116–2123. 4 indexed citations

Bacher, Rhonda, Kieran McGrail, Martha Campbell‐Thompson, et al.. (2024). Serum exocrine pancreas enzymes are biomarkers of immunotherapy response in new-onset type 1 diabetes. Frontiers in Endocrinology. 15. 1497373–1497373. 1 indexed citations

Ebekozien, Osagie, Janine Sanchez, Saketh Rompicherla, et al.. (2023). Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016–2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technology & Therapeutics. 25(11). 765–773. 76 indexed citations breakdown →

Dong, Xiaoru, Daniel J. Perry, Amanda L. Posgai, et al.. (2023). Human immune phenotyping reveals accelerated aging in type 1 diabetes. JCI Insight. 8(17). 21 indexed citations

Sosenko, Jay M., David Cuthbertson, Emily K. Sims, et al.. (2023). Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies. Diabetes Care. 46(5). 1098–1105. 9 indexed citations

Auricchio, Angelo, Aamir Ahmed, Suneet Mittal, et al.. (2023). Mortality benefit of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a real-world analysis. European Heart Journal. 44(Supplement_2). 1 indexed citations

10.

Demeterco‐Berggren, Carla, Osagie Ebekozien, Nudrat Noor, et al.. (2022). Factors Associated With Achieving Target A1C in Children and Adolescents With Type 1 Diabetes: Findings From the T1D Exchange Quality Improvement Collaborative. Clinical Diabetes. 41(1). 68–75. 26 indexed citations

11.

Jacobsen, Laura M., Laura E. Bocchino, John W. Lum, et al.. (2022). Accuracy of Three Commercial Home-Use Hemoglobin A1c Tests. Diabetes Technology & Therapeutics. 24(11). 789–796. 4 indexed citations

12.

Sims, Emily K., David Cuthbertson, Jamie L. Felton, et al.. (2022). Persistence of β-Cell Responsiveness for Over Two Years in Autoantibody-Positive Children With Marked Metabolic Impairment at Screening. Diabetes Care. 45(12). 2982–2990. 5 indexed citations

13.

Nguyen, Hai V., Desmond Schatz, Shweta Mital, Laura M. Jacobsen, & Michael J. Haller. (2021). Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 Diabetes. Diabetes Technology & Therapeutics. 24(4). 258–267. 6 indexed citations

14.

Nathan, Brandon M., María J. Redondo, Heba M. Ismail, et al.. (2021). Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes. Diabetes Care. 45(2). 311–318. 24 indexed citations

15.

Hiller, Helmut, Joseph J. Lebowitz, Stefanie Engler, et al.. (2021). Monogenic Diabetes and Integrated Stress Response Genes Display Altered Gene Expression in Type 1 Diabetes. Diabetes. 70(8). 1885–1897. 7 indexed citations

16.

Demeterco‐Berggren, Carla, Osagie Ebekozien, Saketh Rompicherla, et al.. (2021). Age and Hospitalization Risk in People With Type 1 Diabetes and COVID-19: Data From the T1D Exchange Surveillance Study. The Journal of Clinical Endocrinology & Metabolism. 107(2). 410–418. 22 indexed citations

17.

Jacobsen, Laura M., Brian N. Bundy, Desmond Schatz, et al.. (2020). Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technology & Therapeutics. 22(12). 948–953. 39 indexed citations

18.

Driscoll, Kimberly A., Roy Tamura, Suzanne Bennett Johnson, et al.. (2020). Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study. Pediatric Diabetes. 22(2). 360–368. 17 indexed citations

19.

Stalvey, Michael S., et al.. (2020). Barriers to retinopathy screening in youth and young adults with type 1 diabetes. Pediatric Diabetes. 22(3). 469–473. 6 indexed citations

20.

Sims, Emily K., Susan Geyer, Suzanne Bennett Johnson, et al.. (2019). Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care. 42(12). 2228–2236. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact